Developers of IMM-124E, Immuron Limited, have announced successful Phase II Trial results from testing the drug candidate in an official US-FDA approved clinical trial, involving people with biopsy proven NASH.

The US National Institutes of Health [NIH] grants Emory University funding for a Second Fatty Liver Trial; in Pediatric NASH, using IMM-124E [the underlying technology used in "Protectyn"] Read More HERE

Protectyn's underlying technology turned to yet another disease target! "Autism Spectrum Disorder (ASD)" Read More HERE




What the Protectyn technology all about......

The goal of "Protectyn" [containing IMM-124E] is to offer people an oral immune therapy, for the alteration of the body's systemic immune system, by impacting the guts own immune system.

This is achieved by impacting the mechanism by which the GI immune system, either inhibits or promotes its own reaction towards the oral administration of adjuvnats, antigens and/or antibodies. Read More HERE

"Protectyn" is Available HERE!

Note: Any video content on this page, is for general information purposes only and is not the property of "Protectyn" is a Trademark not owned by and is used on this site for general information purposes only.